Chabner Colloquium

 

November 18, 2019
Boston, Massachusetts USA

 

Bruce Chabner

Founded by Dr. Bruce A. Chabner, this annual symposium, presented in joint partnership with the Massachusetts General Hospital Cancer Center, encourages dialogue among experts on topics that bring cancer biology to clinical application. The Chabner Colloquium is an intensive and thoughtful look at the potential for rational, collaborative drug development, tapping into the resources of government, pharmaceutical and biotech companies, and globally statured cancer centers of excellence.

Focusing on new targets and their interventions; strategies for profiling and selection of patients
for targeted drug trials; and biomarkers and animal models to guide clinical development, the entire drug development process is represented. The Chabner Colloquium provides a dialogue that influences trial design, hastens cancer drug development, and, long-term, will rationalize and lend efficiency to the practice of oncology.

Attendee Quote

Preliminary Agenda

 

Session 1: Promising New Targets for Drug Discovery and Development
Amir Fathi, MD
MGH/Harvard Medical School
IDH therapies
Benjamin Ebert, MD, PhD
Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute
Clonal hematopoiesis of indeterminate potential (CHIP)
Mo Motamedi, PhD
MGH Cancer Center
Epigenetic histone methylation as a target for drug development

 

Session 2: Junior Faculty Forum
Aparna Parikh, MD
MGH/Harvard Medical School
ctDNA as a biomarker of tumor response in colon cancer
Ben Drapkin, MD, PhD
MGH/Harvard Medical School
Biological models for small cell lung cancer
Jessica Lin, MD
MGH/Harvard Medical School
RET as a target in lung cancer
Srinivas Vinod Saladi, PhD
Massachusetts Eye and Ear
Targeting SWI/SNF-Hippo Axis in Squamous Cancers

 

 

 

logos